Jan Balko

Jan Balko

Auto-generated profile, based on publicly available information

Jan Balko

Department of Pathology and Molecular Medicine, Second Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Journal of the European Ceramic Society
Verified
Journal Article
Open access
AKAlexandra Kovalčíková
Alexandra Kovalčíková
JBJán Balko
Ján Balko
Csaba BalázsiCsaba Balázsi
Csaba Balázsi
PHPavol Hvizdos
Pavol Hvizdos
Ján DuszaJán Dusza
Ján Dusza

24 February 2023 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
JBJan Balko
Jan Balko
MSMartin Stanek
Martin Stanek
LKLenka Krskova
Lenka Krskova
JZJosef Zamecnik
Josef Zamecnik
Aims: This retrospective non-randomised study aims to identify new and rare fusion partners withUSP6in the setting of nodular fasciitis. It has been proven, that nodular fasciitis can harbour different variants ofUSP6fusions, which can be used in routine diagnostics and even determine the biological behaviour of the process.Methods: A total of 19 cases of nodular fasciitis examined between 2011 and 2022 at Motol University Hospital in Prague were included into this study. Next to the histopathological evaluation, all cases were assessed using immunohistochemistry, RT-PCR and Anchored multiplex RNA methods. Patient’s main demographic characteristics and corresponding clinical data were also analysed.Results: This study presents one novel (KIF1A) and five rare examples (TMP4, SPARC, EIF5A, MIR22HG, COL1A2) of fusion partners withUSP6among 19 cases of nodular fasciitis.Conclusion: Identification ofUSP6fusion partners in nodular fasciitis helps to understand the biology of such lesions. Moreover, it can be useful in routine histopathological practice of soft-tissues diagnostics, especially in preventing possible misdiagnosis of malignancy.

22 June 2023 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
JBJan Balko
Jan Balko
AOAndrej Ozaniak
Andrej Ozaniak
LKLenka Krskova
Lenka Krskova
Zuzana StrizovaZuzana Strizova
Zuzana Strizova
RLRobert Lischke
Robert Lischke
JZJosef Zamecnik
Josef Zamecnik
Background: Composite haemangioendothelioma is a rare vascular neoplasm with indolent to intermediate malignant potential. Diagnosis of this disease relays on histopathological identification of at least two different morphologically distinctive vascular components in proper clinical settings. Exceedingly rare cases of this neoplasm can exhibit areas resembling high-grade angiosarcoma, which does not change the biological behaviour. Such lesions tend to occur in the setting of chronic lymphoedema and thus, can mimic Stewart-Treves syndrome, which has a much worse clinical outcome and prognosis.Case presentation: We present a case of 49 years old male suffering from chronic lymphoedema of the left lower extremity who had developed a composite haemangioendothelioma with high grade angiosarcoma-like areas mimicking the Stewart-Treves syndrome. Given the multifocality of the disease, the only potentially curable surgical treatment would be hemipelvectomy, which was refused by the patient. The patient has been followed-up, with no signs of local progression of the remaining disease, nor a distant spread outside the involved extremity for two years.Conclusions: Composite haemangioendothelioma represents a rare malignant vascular tumour, with significantly more favourable biological behaviour than angiosarcoma, even in cases where angiosarcoma-like areas are present. For that reason, composite haemangioendothelioma can be easily misdiagnosed as true angiosarcoma. The rarity of this disease unfortunately hampers the development of clinical practice guidelines and the implementation of treatment recommendations. Most of the patients with localized tumour are treated by wide surgical resection, without neo- or adjuvant radiotherapy or chemotherapy. However, in the case of this diagnosis, the watch-and-wait approach is better than mutilating procedure, highlighting the necessity of establishing of the correct diagnosis.

4 August 2022 in Pathology - Research and Practice
Verified
Journal Article
Closed access
JBJan Balko
Jan Balko
JHJan Havlin
Jan Havlin
FCFernando CasasMendez
Fernando CasasMendez
AZAndrea Zajacova
Andrea Zajacova
MKMiroslav Koblizek
Miroslav Koblizek
JZJosef Zamecnik
Josef Zamecnik

1 July 2021 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
AFAlžběta Fíková
Alžběta Fíková
MKMartin Kuchař
Martin Kuchař
DKDavid Kalfert
David Kalfert
LDLucie Dostálová
Lucie Dostálová
JBJan Balko
Jan Balko
JPJan Plzák
Jan Plzák

19 May 2023 in Bone Reports
Verified
Journal Article
Open access
LKLudvík Kašpar
Ludvík Kašpar
JBJan Balko
Jan Balko
MSMartina Strnadová
Martina Strnadová
LKLenka Krsková
Lenka Krsková
DMDavid Máška
David Máška
JZJosef Zámečník
Josef Zámečník
Mazabraud's syndrome represents rare benign disorder characterized by simultaneous occurrence of fibrous dysplasia of bone and intramuscular myxomas within surrounding soft tissue. Mutations of GNAS1 gene were proven to be causative for this condition. Here, we present a case report of a patient with unusual manifestation of this disease, who developed a pathological fracture of the femur in the setting of monostotic fibrous dysplasia. The intramuscular myxoma of the thigh was discovered during the following orthopedic operation, where the intraoperative diagnosis became a pitfall of the case, as the intramuscular myxoma was initially diagnosed as a low-grade sarcoma from the frozen section. Apart from clinical findings, the diagnosis of Mazabraud's syndrome was further proven by histopathological evaluation and molecular studies of GNAS1 gene. This case raises awareness of such condition as it can easily become a diagnostic pitfall.